Sprycel dasatinib regulatory update

Bristol-Myers disclosed in its 3Q10 earnings that it submitted an sNDA in Japan in July for Sprycel dasatinib to treat newly diagnosed chronic myelogenous leukemia (CML). The oral small molecular inhi...